New drug BMS-986435 tested in liver health study

NCT ID NCT07248839

Recruiting now Knowledge-focused Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study is testing how the drug BMS-986435 behaves in the body and whether it is safe for people with mild to moderate liver problems compared to those with healthy livers. 24 adults will receive a single dose, and researchers will measure drug levels and monitor for side effects. The goal is to understand how liver function affects the drug, not to treat any disease directly.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BMS-986435 (also known as MYK-224)
What this could lead to: If successful, this study could help determine safe dosing of BMS-986435 for people with liver problems, potentially leading to better treatment options for heart conditions.
What could go wrong: This is a very early (Phase 1) study with only 24 participants, so results may not apply to larger populations. The drug may cause side effects or not work as expected in people with liver impairment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS HEPATIC IMPAIRMENT

Contacts and locations

Locations

Arizona Clinical Trials
RECRUITING

Chandler, Arizona, 85225, United States
Panax Clinical Research
RECRUITING

Miami Lakes, Florida, 33014, United States
Texas Liver Institute
RECRUITING

San Antonio, Texas, 78215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.